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Background/aim: Since the outbreak of the COVID-19, numerous therapies to counteract this severe disease have emerged. The
benefits of Tocilizumab for severely infected COVID-19 patients and the methodologies of ongoing clinical trials are explored.
Materials and methods: A systematic search adhering to PRISMA guidelines was conducted in PubMed, Cochrane Central, medRxiv,
and bioRxiv using the following keywords: “Tocilizumab,” “Actemra,” “COVID-19.” An additional subsearch was conducted on
Clinicaltrials.gov to locate ongoing tocilizumab trials.
Results: A total of 13 studies were included in the meta-analysis comprising 2120 patients. The treatment group had lower mortality
compared to the control group (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005, I2 = 55%). A descriptive analysis of 50 registered trials was
conducted.
Conclusion: This review meta-analyzed the therapeutic benefits of tocilizumab in COVID-19 patients with severe disease for mortality,
mechanical ventilation, and the characteristics of COVID-19 registered trials.
Key words: Tocilizumab, actemra, coronavirus, COVID-19, clinical trial, cytokine storm syndrome

1. Introduction
Since the outbreak of the novel coronavirus disease 2019
in December 2019, throughout the Hubei province of
China, several clinical trials have been conducted to assess
the benefits of certain therapies. Tocilizumab, also known
as atlizumab, is an immunosuppressive drug, mainly
for the treatment of rheumatoid arthritis and systemic
juvenile idiopathic arthritis, a severe form of arthritis in
children. It is a humanized monoclonal antibody against
the interleukin-6 receptor. Although every observational
study of COVID 19 so far has hinted at the benefits of
drugs that may block inflammatory cytokines, trials of
interleukin 6 inhibitors, such as sarilumab, have yet to
show any viable benefits [1]. As of 13th October 2020, 1.08
million individuals have died due to coronavirus disease
2019 (COVID-19), with 37.6 million cases documented
worldwide. While the death toll reaching over 1 million
individuals worldwide, the results of randomized, doubleblind, placebo-controlled trials have raised questions about
the benefits or tocilizumab in patients with COVID-19 [2].

The World Health Organization (WHO) estimates
that the mortality rate of disease caused by COVID-19 is
3.7%, which is 10 times higher than that seen in influenza
[3]. Afflicted patients may have an overwhelming immune
reaction causing the cytokine storm syndrome with
elements of the Macrophage Activation Syndrome (MAS),
Cytokine-Release Syndrome (CRS), leading to Acute
Respiratory Distress Syndrome (ARDS). SARS-CoV-2 leads
to the production of inflammatory cytokines including
Interleukin-6, which then contributes to cytokine storm
syndromes damaging the lungs and other organs, ultimately
leading to death. IL-6 is a pleiotropic proinflammatory
cytokine produced by many cell types including fibroblasts,
monocytes, and lymphocytes. The SARS-CoV-2 infection
leads to a dose-based production of IL-6 from bronchial
cells [4]. Interleukin inhibitors may help ameliorate severe
damage to the lung tissue caused by cytokine release in
patients infected with severe COVID-19 disease.
As of September 2020, there are 280 COVID-19
clinical trials registered for the treatment of COVID-19
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in clinicaltrials.gov. The clinical course and mortality
outcomes have baffled the population and healthcare
organizations due to the heterogeneity in clinical
presentations with some being asymptomatic to others
acquiring severe pneumonia with respiratory failure
leading to mechanical ventilation or death [5].
While the National Institute of Health guidelines
proposed that insufficient data were present to support the
use of interleukin-6 inhibitors other than for COVID-19
clinical trials, until more concrete evidence is available,
healthcare providers must exercise caution in prescribing
immune-modulating therapies [6]. This meta-analysis
reviews the benefits of Tocilizumab for severe COVID-19
patients and critiques the methodologies of ongoing
clinical trials.
2. Materials and methods
2.1. Search strategy
All potential studies were identified by conducting a
systematic search using PRISMA guidelines. Two databases
were searched to include observational studies including
PubMed (MEDLINE) and Cochrane Central. Additional
studies were located using medRxiv and bioRxiv, in
addition to grey literature sources, such as the WHOCOVID database and Google Scholar. A combination of
keywords was used including “Tocilizumab,” “Actemra”,
and “COVID-19.” An additional search was conducted on
Clinicaltrials.gov to locate all ongoing tocilizumab trials.
2.2. Inclusion and exclusion criteria
All studies comparing the clinical benefits and all-cause
mortality outcomes of tocilizumab were included in the
study. The comparators for the treatment for COVID-19
named as controls in our study were receiving standard
treatment of care or no treatment. Articles published
after January 1st, 2020, were included with no language
restrictions. We excluded 1) case studies, 2) case series,
3) letter to editors, 4) single-arm studies, and 5) two-arm
studies that did not report any outcomes of interest.1
6. National Institutes of Health (2020). COVID-19
Treatment Guidelines Panel. Therapeutic Options Under
Investigation, Coronavirus Disease COVID-19 [online].
Website
https://www.covid19treatmentguidelines.nih.
gov/ [accessed 20 September 2020].
Two early-to-mid level researchers (ZS and AS)
searched the articles independently. All discrepancies
were resolved by the third author (MA). Data were
systematically collected for the primary outcome, which
was mortality in both treatment and control group, and the
secondary outcome, mechanical ventilation using a shared
spreadsheet for the meta-analysis. For all ongoing clinical

trial registrations, findings were tabulated as 1) clinical
trial identifier, 2) study design, 3) estimated enrollment,
4) conditions, 5) phase of the study, 6) interventions
(experimental vs. comparator), 7) primary outcome
measure and 8) recruitment status.
2.3. Objectives
The primary objective was to determine whether
tocilizumab reduced the risk of mortality in the treatment
groups. The secondary objective was to identify if the risk
of mechanical ventilation was higher in either group.
2.4. Data analysis
All analyses were carried using Review Manager V5.4. The
Mantel–Haenszel random-effects model was used with
95% confidence intervals. A test of P ≤ 0.05 was considered
significant. A presentation of the Unadjusted Odds ratios
(ORs) was given for dichotomous variables (I. mortality
and II. mechanical ventilation). The I2 index was identified
to assess heterogeneity among the included studies. A
funnel plot was generated for visual inspection if more
than 10 studies were included in either analysis. The study
was not registered in an online register due to the timesensitivity of the topic.
3. Results
We included 13 studies in the meta-analysis [5,7–17]. There
were a total of 2120 patients, with 674 (31.8%) patients in
the tocilizumab group and 1446 (68.2%) patients in the
control group. Our results indicate that patients treated
with tocilizumab had lower risks of mortality as compared
to those who received no treatment or standard COVID-19
therapies (OR = 0.42, 95% CI = 0.26 to 0.69, P = 0.0005).
There was moderate heterogeneity in included studies (I2 =
55%) (Figure 1), whereas, the risk of mechanical ventilation
was inconclusive in those who obtained tocilizumab
therapy (OR = 0.95, 95% CI = 0.53 to 1.72, P = 0.88, I2
= 61%) (Figure 2). The included studies provide clear
evidence that the treatment group has a lower risk of death
in severe COVID-19 patients, requiring further proof in
the form of randomized controlled trials. However, the
findings do not identify a clear demarcation of risks of
mechanical ventilation between the treatment and control
groups. Publication bias was noted within acceptable
limits and high to moderate level methodological studies
were included in our analysis (Figure 3).
Using the keywords “COVID-19” and “tocilizumab,”
a total of 67 studies were located on Clinicaltrials.gov,
of which we present a total of 50 registered trails. Of all,
we included 4(8%) nonrandomized, open-label studies,
7(14%) randomized, double-masked (participant and

National Institutes of Health (2020). COVID-19 Treatment Guidelines Panel. Therapeutic Options Under Investigation, Coronavirus Disease COVID-19 [online]. Website https://www.covid19treatmentguidelines.nih.gov/ [accessed 20 September 2020].
1

891

SARFRAZ et al. / Turk J Med Sci

Figure 1. Mortality associations between the tocilizumab group and the control group.

Figure 2. Odds of mechanical ventilation between the tocilizumab group and the control group.

Figure 3. Funnel plot showing publication bias of included studies. Each dot represents a single study. The X axis shows the result of the
study expressed as an odds ratio for mortality in tocilizumab and control groups. The Y axis is the standard error of the effect estimate.
The shape is asymmetrical as it does not resemble that of an inverted funnel or a pyramid representing publication bias. Given that the
I2 value was 55%, study heterogeneity may have led to an asymmetrical funnel.
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Table. Characteristics of registered tocilizumab trials.
No

Clinical trial
identifier

Study designs

1

NCT04331795

2

Estimated
Enrollment

Interventions

Primary outcome measures

Recruitment
status

Nonrandomized, open label 32

Phase 2

Tocilizumab

Clinical response

Completed

NCT04339712

Nonrandomized, open label 40

Phase 2

Anakinra, Tocilizumab

Change of baseline total sequential organ failure
assessment (SOFA) score|

Recruiting

3

NCT04492501

Nonrandomized, open label 600

Not Applicable

Therapeutic plasma exchange, convalescent plasma,
tocilizumab, remdesivir, Mesenchymal stem cell therapy

Survival

Completed

4

NCT04423042

Non-Randomized, open
label

30

Phase 3

Tocilizumab

All-cause mortality

Not yet
recruiting

5

NCT04438980

Randomized, double
masking between participant 72
and investigator

Phase 3

Methylprednisolone vs. Placebo

Proportion of patients developing treatment
failure and Mortality at day 28

Recruiting

6

NCT04412772

Randomized, double
masking between participant 300
and investigator

Phase 3

Tocilizumab vs. Placebo

Clinical status (on a 7-point ordinal scale) at
day 28

Recruiting

7

NCT04356937

Randomized, double
masking between participant 243
and investigator

Phase 3

Tocilizumab vs. Placebo

The time from administration of the
investigational agent (or placebo) to requiring
mechanical ventilation and intubation, or death
for subjects who die prior to intubation|

Active, not
recruiting

8

NCT04372186

Randomized, double
masking between participant 379
and investigator

Phase 3

Tocilizumab vs. Placebo

Cumulative Proportion of Participants
Requiring Mechanical Ventilation by Day 28

Active, not
recruiting

9

NCT04320615

Randomized, double
masking between participant 450
and investigator

Phase 3

Tocilizumab vs. Placebo

Clinical Status Assessed Using a 7-Category
Ordinal Scale

Completed

10

NCT04409262

Randomized, double
masking between participant 450
and investigator

Phase 3

Remdesivir, Tocilizumab vs. Placebo

Clinical Status as Assessed by the Investigator
Using a 7-Category Ordinal Scale of Clinical
Status on Day 28

Recruiting

11

NCT04380519

Randomized, double
masking between participant 372
and investigator

Phase 2|Phase 3

RPH-104 80 mg, Olokizumab 64 mg; vs. Placebo

Proportion of patients, responded to the study
therapy, in each of the treatment groups

Recruiting

12

NCT04479358

Randomized, open label

332

Phase 2

Tocilizumab vs. Standard of Care

Time to Recovery, Achievement of Recovery and Not yet
Overall Survival
recruiting

13

NCT04345445

Randomized, open label

310

Phase 3

Tocilizumab, Methylprednisolone

The proportion of patients requiring mechanical Not yet
ventilation
recruiting

14

NCT04435717

Randomized, open label

78

Phase 2

Tocilizumab 20 MG/ML Intravenous Solution;
Drug: Tocilizumab 20 MG/ML Intravenous Solution (2 doses)

Change in IL-12 values in the 3 study groups
from the start of treatment (Day 0) and on days
1 and 3

Recruiting

15

NCT04377750

Randomized, open label

500

Phase 4

Tocilizumab

Survival

Recruiting

16

NCT04332094

Randomized, open label

276

Phase 2

Tocilizumab, Hydroxychloroquine, Azithromycin

In-hospital mortality

Recruiting

17

NCT04377659

Randomized, open label

40

Phase 2

Tocilizumab

Progression of respiratory failure or death

Recruiting

SARFRAZ et al. / Turk J Med Sci

893

Current phase
(Updated 9/14/2020)

894

Table. (Continued).
NCT04412291

Randomized, open label

120

Phase 2

Anakinra Prefilled Syringe, Tocilizumab Prefilled Syringe vs.
Standard-of-care treatment

Time to recovery and Mortality

Recruiting

19

NCT04346355

Randomized, open label

126

Phase 2

Tocilizumab

Entry into Intensive Care with invasive
mechanical ventilation or death from any cause
or clinical aggravation

Terminated

20

NCT04377503

Randomized, open label

40

Phase 2

Tocilizumab 180 MG/ML, Methylprednisolone Sodium
Succinate

Patient clinical status 15 days after
randomization

Not yet
recruiting

21

NCT04363736

Randomized, open label

100

Phase 2

Tociliuzumab

Serum Concentration of interleukin-6 (IL-6)
Following Administration of 8 mg/kg IV TCZ

Completed

22

NCT04361032

Randomized, open label

260

Phase 3

Tocilizumab Injection, Deferoxamine

Mortality rate

Not yet
recruiting

23

NCT04424056

Randomized, open label

216

Phase 3

Anakinra, Ruxolitinib vs. Standard of care

Ventilation free days at day 28

Not yet
recruiting

24

NCT04403685

Randomized, open label

129

Phase 3

Tocilizumab

Evaluation of clinical status and All-cause
mortality

Terminated

Recruiting

25

NCT04335305

Randomized, open label

24

Phase 2

Tocilizumab, Pembrolizumab (MK-3475)

Percentage of patients with normalization of
SpO2 on room air (measured without any
respiratory support for at least 15 minutes) and
Proportion of patients discharged from the
emergency department and classified as low risk

26

NCT04333914

Randomized, open label

384

Phase 2

Chloroquine analog (GNS651), Nivolumab, Tocilizumab,
Standard of care, Avdoralimab, Monalizumab

28-day survival rate and Time to clinical
improvement

Suspended

27

NCT04476979

Randomized, open label

120

Phase 2

Tocilizumab, Dexamethasone

Survival without needs of ventilator utilization
at day 14 and WHO progression scale at day 7
and 14

Recruiting

28

NCT04361552

Randomized, open label

0

Phase 3

Best Practice, Tocilizumab

7-day length of invasive mechanical ventilation
(MV)

Withdrawn

29

NCT04330638

Randomized, open label

342

Phase 3

Usual Care, Anakinra, Siltuximab, Tocilizumab

Time to Clinical Improvement|

Recruiting

30

NCT04331808

Randomized, open label

228

Phase 2

Tocilizumab

Survival without needs of ventilator utilization at Active, not
day 14. Group 1
recruiting

31

NCT04322773

Randomized, open label

200

Phase 2

RoActemra IV vs. Standard medical care

Time to independence from supplementary
oxygen therapy

32

NCT04381936

Randomized, open label

15000

Phase 2|Phase 3

Lopinavir-Ritonavir, Corticosteroid, Hydroxychloroquine,
Azithromycin, Convalescent plasma, Tocilizumab,
Immunoglobulin

All-cause mortality and Duration of hospital stay Recruiting

33

NCT04536363

Randomized, open label

284

Phase 2

Analogs, Prostaglandin vs. Standard therapeutic protocol

Mortality and Hypoxemia Resolution

Not yet
recruiting

34

NCT04359095

Randomized, open label

1600

Phase 2|Phase 3

Hydroxychloroquine|Drug, Lopinavir / Ritonavir Pill,
Azithromycin, vs. Standard treatment

Mortality

Not yet
recruiting

Recruiting
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NCT02735707

Randomized, open label

7100

Phase 4

36

NCT04374539

Randomized, open label

116

Phase 2

Plasma exchange vs. Standard medical treatment

Impact of plasma exchange

Recruiting

Recruiting

Active, not
recruiting

All-cause mortality

Recruiting

37

NCT04366245

Randomized, open label

72

Phase 1|Phase 2

Hyperimmune plasma vs Standard of care for SARS-CoV-2
infection

Safety: Incidence of Adverse Events and
Serious Adverse Events grade 3 and 4, related
to the product under investigation or the
administration procedure, graduated according
to the common toxicity criteria scale (CTCAE)

38

NCT04346693

Randomized, open label

320

Phase 3

Standard therapy recommended by the Ministry of Health of
the Russian Federation and Dalargin intramuscular injection

The change of viral load in patients with SARSCOVID-19

39

NCT04401410

Randomized, open label

58

Phase 1

Dose Finding Phase (MTD), Partially HLA-matched SARSCoVSTs, Routine care

Graft versus Host Disease (GvHD) and Cytokine Not yet
Release Syndrome (CRS)
recruiting

40

NCT04392414

Randomized, open label

60

Phase 2

COVID-19 convalescent hyperimmune plasma, Nonconvalescent fresh frozen plasma (Standard plasma)

30-day mortality rate

Recruiting

41

NCT04414631

Randomized, open label

120

Phase 2

Conestat alfa

Disease severity and Time to clinical
improvement

Recruiting

NCT04335071

Randomized, quadruple
masking among participant,
100
care provider, investigator,
and outcomes assessor

Phase 2

Tocilizumab, Placebo

Number of patients with ICU admission,
intubation and death

Recruiting

43

NCT04349410

Randomized, single
masking for investigator

500

Phase 2|Phase 3

Hydroxychloroquine, Azithromycin/ Doxycycline/
Clindamycin/ Primaquine - low dose, Clindamycin,
Primaquine - high dose, Remdesivir, Tocilizumab,
Methylprednisolone, Interferon-Alpha2B, Losartan,
Convalescent Serum

Improvement in FMTVDM Measurement with
nuclear imaging, Ventilator status, and survival
status

Enrolling by
invitation

44

NCT04445272

Single group, open label

500

Phase 2

Tocilizumab

Mortality rate and metrics of respiratory function Recruiting

45

NCT04317092

Single Group, open label

400

Phase 2

Tocilizumab Injection

One-month mortality rate

Recruiting

46

NCT04363853

Single Group, open label

200

Phase 2

Tocilizumab

Hematic biometry and Blood chemistry

Recruiting

47

NCT04370834

Single group, open label

217

Phase 2

Tocilizumab

Clinical outcome as evaluated by the 7-category
Clinical Status Ordinal Scale

Suspended

48

NCT04315480

Single group, open label

38

Phase 2

Tocilizumab

arrest in deterioration of pulmonary function
and death

Active, not
recruiting

49

NCT04386239

Single Group, open label

40

Early Phase 1

Sarilumab Prefilled Syringe

Proportion of patients who show an
improvement of the respiratory function

Not yet
recruiting

50

NCT04335123

Single Group, open label

50

Phase 1

Losartan

Number of participants with treatment-related
adverse events as assessed by protocol definition
of AE

Recruiting

42
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Fixed-duration Hydrocortisone, Shock-dependent
hydrocortisone, Ceftriaxone, Moxifloxacin or Levofloxacin,
Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate,
Macrolide administered for 3-5 days or 14 days, 5/10-days
oseltamivir, Lopinavir/ritonavir, Hydroxychloroquine
Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon1a Anakinra, Fixed-duration higher dose Hydrocortisone,
Tocilizumab, Sarilumab, Vitamin C, Therapeutic
anticoagulation, Simvastatin, Convalescent plasm,
Protocolised mechanical ventilation strategy
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investigator) studies, 30(60%) randomized, openlabel studies, 1(2%) randomized, quadruple masking
(participant, care provider, investigator, outcomes assessor)
study, 1(2%) randomized, single masking (investigator)
study, and 7(14%) single group, open-label studies (Table).
4. Discussion
To the best of our knowledge, this is the first review
that meta-analyses the benefits of tocilizumab in severe
COVID-19 patients along with reviewing methodologies
of ongoing clinical trials. Our findings must be read with
caution due to the lack of strong evidence from randomized
controlled trials. Tocilizumab is the humanized antiIL-6 receptor monoclonal antibody that is approved
specifically for cytokine release syndrome, systematic
juvenile idiopathic arthritis, and rheumatic arthritis [18].
The results indicate that tocilizumab improves mortality
outcomes in severely infected COVID-19 patients;
however, the results do not elucidate clear demarcation
of risks of mechanical ventilation between treatment and
control groups.
The National Institute of Health published Interim
guidelines suggesting that tocilizumab may be considered
for COVID-19 patients meeting the following six criteria,
who are otherwise ineligible for steroid therapy [19]. The
patient 1) must be COVID-19 positive, 2) must have
abnormal chest imaging as seen in coronavirus infections,
worsening respiratory status over 1–2 days necessitating
4–6 L/min of oxygen, 3) must not have any systemic
fungal or bacterial co-infection, 4) must be suspected
for cytokine release syndrome support by an elevation
of inflammatory markers (for example, D-dimer > 1
mg/L, Ferritin > 600 ug/mL, LDH > 250U/L), along with
clinical decline, 5) must not have had a poor prognosis
indicating an unlikely survival of over 48 h, and 6) must
have received mechanical ventilation for 24 h or less.
Of the studies included in the meta-analysis, Somers
et al. only tested the benefits of tocilizumab on severe
COVID-19 patients obtaining mechanical ventilation.
The duration of mechanical ventilation among the
tocilizumab and control group was 13.8d (IQR: 7.1d,
27.5d) and 13d (IQR: 8.1d, 23.5d), respectively [12].
It is noted that the benefits of tocilizumab therapy on
patients who have been mechanically ventilated patients
for over 24 h may be low due to low chances of clinical
improvement.2
However, 56% of patients (n = 76) in the treatment
group were discharged alive by the end of follow-up
process as compared to 30% of patients (n = 76) in the
control group suggesting that the clinical benefits must be
assessed in the ongoing placebo-controlled trials. In the

COVACTA trial, where 452 severe COVID-19 patients
were randomized, improvements in clinical status at day
28 and mortality outcomes were not observed [20]. Both
the safety and efficacy of tocilizumab must be assessed for
patients with severe disease in the several randomized,
double-blind, placebo-controlled phase 3 trials namely
COVACTA, REMDACTA, and EMPACTA to corroborate
the true benefits of the drug in acute care settings.
Our meta-analytical findings have limitations. Most of
the included studies were retrospective cohorts; however,
updated preprints of placebo-controlled trials solidified
our findings. There was a lack of diagnostic criteria
for severe COVID-19 between all studies that led to a
difference in mechanical ventilation outcomes between
the treatment and control groups. The inflammatory
markers reduced ventilatory support requirements, and
radiological improvement signs were not always presented
in the included studies.
5. Recommendations
All placebo-controlled trials must ascertain the optimal
dosage of tocilizumab and the potential utility of multiple
dosages. IL-6 serum concentration tests must be made
routinely available when tocilizumab response is to be
assessed [12]. Drug administration in the acute care
setting ought to be guided by strict institutional criteria,
thus being completely standardized. In addition to the
regular follow up period of 28 days, the full course of
hospitalization ought to be determined to characterize
long-term sequelae in treatment and control groups.
6. Conclusion
Anti-IL-6 drugs for COVID-19 are a cause of contention
since the outbreak of the global pandemic. Tocilizumab,
which has had mixed results in RCTs, is being utilized
off-label and as an experimental therapy for patients
with COVID-19 who are sick or deteriorating with a
slight chance of recovery. The ongoing pandemic has
created ethical challenges concerning the nonapproved
use among patients and choosing the most appropriate
patient to receive the experimental therapy in the setting
of ongoing randomized controlled trials [21]. The review
attempted to link the key tocilizumab studies, find benefits
in case of mortality and the risk of mechanical ventilation
by the end of treatment, to steer the narrative for ongoing
registered trials, which will ultimately form the fate for the
use of tocilizumab in COVID-19.
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